Factors influencing cognitive performance after 1-year treatment with direct oral anticoagulant in patients with atrial fibrillation and previous ischemic stroke: a pilot study

• Published in: Journal of thrombosis and thrombolysis 2021-04, Vol.51 (3), p.767-778
• Main Authors: Cappellari, Manuel, Forlivesi, Stefano, Zucchella, Chiara, Valbusa, Valeria, Sajeva, Giulia, Musso, Anna Maria, Micheletti, Nicola, Tomelleri, Giampaolo, Bovi, Tommaso, Bonetti, Bruno, Bovi, Paolo
• Format: Article
• Language: English
• Subjects: Anticoagulants; Cardiac arrhythmia; Cardiology; Cardiovascular disease; Cognitive ability; Congestive heart failure; Coronary artery disease; Dementia disorders; Fibrillation; Heart failure; Hematology; Hyperlipidemia; Ischemia; Medicine; Medicine & Public Health; Patients; Stroke
• ISSN: 0929-5305; 1573-742X
• DOI: 10.1007/s11239-020-02233-1

Anticoagulant treatment as stroke prevention, particularly direct oral anticoagulant (DOAC), may reduce the risk of dementia in patients with atrial fibrillation (AF). We aimed to assess factors influencing cognitive performance after 1-year treatment with DOAC in patients with AF and previous ischemic stroke. We recruited 33 ischemic stroke patients who were discharged from Verona Stroke Unit with diagnosis of AF and prescription of treatment with DOAC. For each cognitive test, we estimated the effect of T0 (first session) variables on T1 (1-year session) cognitive performance using ordinal logistic regression fitted to a 1 point-shift from 4 to 0 on ESs. The effect of T0 clinical variables was presented as odds ratio (OR) with 95% confidence interval (CI) after adjustment for T0 total score of the corresponding cognitive test. Sustained AF (OR: 4.259, 95% CI 1.071–16.942) and ischemic heart disease (OR: 6.654, 95% CI 1.329–33.300) showed a significant effect on T1 MoCA Test; congestive heart failure on T1 RAVLT Immediate recall (OR: 9.128, 95% CI 1.055–78.995), T1 RAVLT Delayed recall (OR: 7.134, 95% CI 1.214–52.760), and T1 Trail Making Test (Part A) (OR: 16.989, 95% CI 1.765–163.565); sustained AF (OR: 5.055, 95% CI 1.224–20.878) and hyperlipidemia (OR: 4.764, 95% CI 1.175–19.310) on T1 Digit span forward Test; ischemic heart disease (aOR: 8.460, 95% CI 1.364–52.471) on T1 Stroop Color and Word Test (time); Dabigatran use (aOR: 0.084, 95% CI 0.013–0.544) on FAB; age ≥ 75 years (aOR: 0.058, 95% CI 0.006–0.563) and hyperlipidemia (aOR: 5.809, 95% CI 1.059–31.870) on T1 Phonemic word fluency Test; female sex (aOR: 6.105, 95% CI 1.146–32.519), hyperlipidemia (aOR: 21.099, 95% CI 2.773–160.564), total Modified Fazekas Scale score > 1 (aOR: 78.530, 95% CI 3.131–1969.512) on Semantic word fluency Test. Sustained AF, ischemic heart disease, congestive heart failure, hyperlipidemia, and female sex were the factors influencing cognitive performance after 1-year treatment with DOAC in patients with AF and previous ischemic stroke. Modified Fazekas Scale score in the first session was the only radiological variable that had a significant effect on cognitive performance.